Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Seen & Heard: Charles River Tries Not To “Freeze Out” Big Pharma Clients In China - CEO

This article was originally published in PharmAsia News

Executive Summary

A new facility that Charles River Laboratories is renovating in Shanghai has triggered overwhelming interest from the contract research organization's big pharma customers, CEO Jim Foster said March 19 during a presentation at the Lehman Brothers Healthcare conference in Miami

You may also be interested in...



Charles River Set To Launch First Global CRO Preclinical Testing Center In China

BEIJING - Charles River Laboratories, one of the world's leading contract research organizations, is set to open a new preclinical testing facility this week in the rapidly expanding Chinese market, according to Senior VP Christopher Perkins

Charles River Set To Launch First Global CRO Preclinical Testing Center In China

BEIJING - Charles River Laboratories, one of the world's leading contract research organizations, is set to open a new preclinical testing facility this week in the rapidly expanding Chinese market, according to Senior VP Christopher Perkins

Shanghai ChemPartner CEO Michael Hui On Finding A Niche In China Amidst Increasing Foreign Competition: An Interview With PharmAsia News (Part 2 of 2)

Shanghai ChemPartner was set up in 2003 at Shanghai's Zhangjiang Hi-Tech Park, and today it is one of the leading R&D outsourcing providers in China. PharmAsia News recently visited company headquarters to meet Michael Hui, CEO of ChemPartner - as well as sister company ChemExplorer, and their holding company ShangPharma - to discuss the company's recent deal with private equity investment firm TPG, as well as handling increased competition from foreign firms moving into China.

UsernamePublicRestriction

Register

SC141576

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel